Effect of stereotactic body radiotherapy dose escalation plus pembrolizumab and trametinib versus stereotactic body radiotherapy dose escalation plus gemcitabine for locally recurrent pancreatic cancer after surgical resection on survival outcomes: A secondary analysis of an open-label, randomised, controlled, phase 2 trial

BACKGROUND: There are a lack of studies about whether radiation dose escalation synergizes with immunotherapy and targeted therapy in pancreatic cancer. In this study, we performed a secondary analysis to investigate whether a high radiation dose rather than a low dose plus pembrolizumab and trameti...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Xiaofei, Liu, Wenyu, Cao, Yangsen, Ju, Xiaoping, Zhao, Xianzhi, Jiang, Lingong, Ye, Yusheng, Zhang, Huojun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9718952/
https://www.ncbi.nlm.nih.gov/pubmed/36471691
http://dx.doi.org/10.1016/j.eclinm.2022.101764

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9718952/
https://www.ncbi.nlm.nih.gov/pubmed/36471691
http://dx.doi.org/10.1016/j.eclinm.2022.101764

Ejemplares similares